COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
01/05/2025
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial [...]
Amwell® Announces Results for First Quarter 2025
01/05/2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March [...]
Sutro Biopharma to Participate in Upcoming Investor Conferences
01/05/2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), [...]
Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information
01/05/2025
WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it plans to release [...]
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
01/05/2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its first quarter 2025 financial results will be released before market open on [...]
Option Care Health to Participate in Upcoming Investor Conferences
01/05/2025
BANNOCKBURN, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Stryker reports first quarter 2025 operating results
01/05/2025
Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billion Organic net sales [...]
Streamline Health® Announces New eValuator™ Contract with Ohio-Based Health System
01/05/2025
1,100 bed health system selects eValutor’s pre-bill code audit technology to improve coding accuracy ATLANTA, May 01, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of [...]
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
01/05/2025
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Zevra Therapeutics to Participate in the Citizens Life Science Conference
01/05/2025
CELEBRATION, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s [...]
Kura Oncology Reports First Quarter 2025 Financial Results
01/05/2025
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral [...]
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
01/05/2025
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 [...]
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
01/05/2025
WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
01/05/2025
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with [...]
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
01/05/2025
Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 [...]
Aura Biosciences to Participate in Upcoming Investor Conferences
01/05/2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced [...]
Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition
01/05/2025
Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 members Exceeds high-end of Q1 guidance on membership, revenue, adjusted [...]
Ascendis Pharma Reports First Quarter 2025 Financial Results
01/05/2025
- Q1 2025 revenue of €44.7 million for YORVIPATH ® and €51.3 million for SKYTROFA ® - TransCon ™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial ( TransCon CNP + [...]
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
01/05/2025
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations [...]

Pages